Dominick P Trombetta1, Debra A Heller2. 1. Associate Professor, Pharmacy Practice, Wilkes University, School of Pharmacy, Wilkes-Barre, PA. 2. Senior Health Outcomes Scientist, Magellan Rx Management/PACE, Harrisburg, PA.
Abstract
BACKGROUND: Publicly funded prescription drug programs, such as state pharmacy assistance programs, provide critical benefits for the care of individuals, but they are frequently limited in their resources to optimize patient outcomes. The application of quality metrics to prescription drug claims may help to determine whether prescribers' adherence to national standards can be augmented through academic detailing. OBJECTIVE: To evaluate changes in diabetes drug prescribing patterns after an academic detailing educational intervention in 2013 and 2014 for prescribers in the Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE) program. METHODS: We used a retrospective, quasiexperimental study design that applied interrupted time series and segmented regression analysis, and examined PACE pharmacy claims data for 1 year before and 1 year after the academic detailing intervention. Four diabetes prescribing metrics were evaluated at monthly intervals for a sample of 574 prescribers who received academic detailing and for a propensity score-matched comparison sample of 574 prescribers who did not receive the intervention. RESULTS: The prescribers who received academic detailing did not differ significantly after the intervention from the providers who did not receive the intervention in their prescribing trends for the 4 diabetes metrics. The observed time series patterns suggest that diabetes-related ceiling effects were likely, with relatively small room for improvement at the group level during the study period. CONCLUSION: The results of this study did not demonstrate group differences in prescribing trends that were attributable to the intervention. However, many prescribers in the detailed group had been exposed to similar educational outreach by PACE before 2013, which limits the interpretation of this finding. In addition, the diabetes quality metrics had been the standard of care during the preceding decade, with a broad dissemination of the treatment guidelines to the provider community. These results are consistent with a ceiling effect in the measured metrics, suggesting that most prescribers in both groups were largely following core diabetes guidelines before and after the intervention.
BACKGROUND: Publicly funded prescription drug programs, such as state pharmacy assistance programs, provide critical benefits for the care of individuals, but they are frequently limited in their resources to optimize patient outcomes. The application of quality metrics to prescription drug claims may help to determine whether prescribers' adherence to national standards can be augmented through academic detailing. OBJECTIVE: To evaluate changes in diabetes drug prescribing patterns after an academic detailing educational intervention in 2013 and 2014 for prescribers in the Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE) program. METHODS: We used a retrospective, quasiexperimental study design that applied interrupted time series and segmented regression analysis, and examined PACE pharmacy claims data for 1 year before and 1 year after the academic detailing intervention. Four diabetes prescribing metrics were evaluated at monthly intervals for a sample of 574 prescribers who received academic detailing and for a propensity score-matched comparison sample of 574 prescribers who did not receive the intervention. RESULTS: The prescribers who received academic detailing did not differ significantly after the intervention from the providers who did not receive the intervention in their prescribing trends for the 4 diabetes metrics. The observed time series patterns suggest that diabetes-related ceiling effects were likely, with relatively small room for improvement at the group level during the study period. CONCLUSION: The results of this study did not demonstrate group differences in prescribing trends that were attributable to the intervention. However, many prescribers in the detailed group had been exposed to similar educational outreach by PACE before 2013, which limits the interpretation of this finding. In addition, the diabetes quality metrics had been the standard of care during the preceding decade, with a broad dissemination of the treatment guidelines to the provider community. These results are consistent with a ceiling effect in the measured metrics, suggesting that most prescribers in both groups were largely following core diabetes guidelines before and after the intervention.
Entities:
Keywords:
PACE program; academic detailing; diabetes guidelines; educational outreach; medication prescribing patterns; prescription drug benefit program; quality metrics; type 2 diabetes
Authors: Jennifer M Polinski; M Alan Brookhart; Jeffrey N Katz; Marilyn Arnold; Judy Kristeller; Dominick Trombetta; Mary Elizabeth Doyle Tadduni; Mary Jean Golomb; Daniel H Solomon Journal: Pharmacoepidemiol Drug Saf Date: 2005-12 Impact factor: 2.890
Authors: Remo Ostini; Desley Hegney; Claire Jackson; Margaret Williamson; Judith M Mackson; Karin Gurman; Wayne Hall; Susan E Tett Journal: Ann Pharmacother Date: 2009-03-03 Impact factor: 3.154
Authors: Daniel H Solomon; M Alan Brookhart; Jennifer Polinski; Jeffrey N Katz; Danielle Cabral; Andrea Licari; Jerry Avorn Journal: Contemp Clin Trials Date: 2005-01-27 Impact factor: 2.226
Authors: Philippe Ricordeau; Pierre Durieux; Alain Weill; Gilles Chatellier; Nathalie Vallier; Alvine Bissery; Pierre Fender; Hubert Allemand Journal: Int J Technol Assess Health Care Date: 2003 Impact factor: 2.188
Authors: M A O'Brien; S Rogers; G Jamtvedt; A D Oxman; J Odgaard-Jensen; D T Kristoffersen; L Forsetlund; D Bainbridge; N Freemantle; D A Davis; R B Haynes; E L Harvey Journal: Cochrane Database Syst Rev Date: 2007-10-17